PHC Corporation’s Biomedical Division, known as PHCbi, has recently announced the launch of its advanced cell expansion system, LiCellGrow. This innovative technology is specifically designed for research purposes in Japan and select global markets, aiming to enhance the production quality of cell and gene therapies.
Real-Time Monitoring for Optimal Conditions
LiCellGrow offers a unique capability for developers by allowing for automatic control of culture conditions. This system enables real-time visualization of metabolic changes in cells, enhancing the overall efficiency of therapy development. By integrating cutting-edge In-Line monitoring technology, LiCellGrow continuously tracks glucose and lactate concentrations—key indicators of cellular metabolism.
Advanced Control Technology
The control technology embedded within LiCellGrow utilizes metabolic measurements to optimize the timing of cell culture medium adjustments. This innovative approach is grounded in PHCbi’s extensive experience in electrochemical measurement platforms, which have evolved over three decades, primarily through advancements in blood glucose sensor technology.
Consistency and Quality Assurance
By tracking metabolic data in real time, LiCellGrow ensures that medium exchanges occur at the most suitable intervals. This meticulous monitoring supports the maintenance of consistent product quality and aligns with quality by design principles essential for scientifically rigorous manufacturing processes. As a result, developers can expect a higher level of reliability in their cell therapy products.
User-Friendly Single-Use Design
One of the standout features of LiCellGrow is its single-use design that incorporates dedicated culture bags. These bags can easily be placed inside standard CO₂ incubators, eliminating the need for specialized facility requirements. This user-friendly approach simplifies the integration of the system into existing laboratory environments.
Building on Previous Innovations
LiCellGrow builds upon the foundation established by the earlier LiCellMo, a live cell metabolic analyzer designed for research applications. The introduction of LiCellGrow reflects PHCbi’s commitment to advancing technologies that address common challenges faced by therapy developers in terms of quality, cost, and delivery.
Future Developments in the Pipeline
Looking ahead, PHCbi has ambitious plans to expand its product offerings between late 2026 and early 2028. Upcoming innovations will include culture bags equipped with filtration functions, dissolved oxygen meter units, and cGMP-compliant consumables. These developments are poised to further enhance the capabilities of researchers and developers in the field of cell and gene therapy.
Commitment to Advanced Therapies
Chikara Takauo, Director of PHC Corporation and head of PHCbi, expressed enthusiasm about the launch of LiCellGrow, emphasizing its potential to address pressing challenges in the realm of cell and gene therapies. He noted that the system represents a significant advancement in making the manufacturing processes for these therapies more efficient, reliable, and scalable. PHCbi remains dedicated to fostering the adoption of cell and gene therapies and other advanced treatment options for challenging medical conditions.
Key Takeaways
- LiCellGrow enhances the quality and efficiency of cell and gene therapy production through real-time monitoring and control.
- The system’s single-use design simplifies integration into standard laboratory environments, promoting ease of use.
-
Future expansions will include additional features and consumables to further support the needs of therapy developers.
In conclusion, LiCellGrow marks a pivotal development in the landscape of cell therapy manufacturing, offering researchers a robust tool to streamline processes and improve outcomes. As PHCbi continues to innovate, the potential for transformative advancements in therapy development becomes increasingly promising.
Read more → www.yahoo.com